2021
DOI: 10.1016/j.jinorgbio.2021.111549
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis, characterization of ruthenium(II), nickel(II), palladium(II), and platinum(II) triphenylphosphine-based complexes bearing an ONS-donor chelating agent: Interaction with biomolecules, antioxidant, in vitro cytotoxic, apoptotic activity and cell cycle analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

12
43
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 57 publications
(55 citation statements)
references
References 121 publications
12
43
0
Order By: Relevance
“…The observed spectral features of the Zn­(II) complex observed at 231 and 259 were assigned to π → π* and 303 and 393 to n → π* transitions, and those of the Cu­(II) complex at the spectral band of 255 nm was assigned to the n → π* transition. , Additionally, the broad band observed at 351 nm for Cu­(II) may be assigned to the ligand-to-metal charge transfer (LMCT), in line with our DFT calculations (Figure ), which showed the presence of electron transitions from the highest occupied molecular orbital (HOMO) of the ligand to the lowest unoccupied molecular orbital (LUMO) of the metal center. ,,, There is no d → d transition band for the Cu­(II) complex; however, ligand-to-metal charge transfer (LMCT) was observed to be dominant, in agreement with the literature. , This is due to the vacant d-orbital of the Cu­(II) complex and the presence of lone-pair electrons on the ligand. , Similar trends were found in the TD-DFT-calculated absorption spectra (Figures and S9).…”
Section: Resultssupporting
confidence: 84%
See 1 more Smart Citation
“…The observed spectral features of the Zn­(II) complex observed at 231 and 259 were assigned to π → π* and 303 and 393 to n → π* transitions, and those of the Cu­(II) complex at the spectral band of 255 nm was assigned to the n → π* transition. , Additionally, the broad band observed at 351 nm for Cu­(II) may be assigned to the ligand-to-metal charge transfer (LMCT), in line with our DFT calculations (Figure ), which showed the presence of electron transitions from the highest occupied molecular orbital (HOMO) of the ligand to the lowest unoccupied molecular orbital (LUMO) of the metal center. ,,, There is no d → d transition band for the Cu­(II) complex; however, ligand-to-metal charge transfer (LMCT) was observed to be dominant, in agreement with the literature. , This is due to the vacant d-orbital of the Cu­(II) complex and the presence of lone-pair electrons on the ligand. , Similar trends were found in the TD-DFT-calculated absorption spectra (Figures and S9).…”
Section: Resultssupporting
confidence: 84%
“… 24 , 71 , 74 , 76 There is no d → d transition band for the Cu(II) complex; however, ligand-to-metal charge transfer (LMCT) was observed to be dominant, in agreement with the literature. 74 , 77 This is due to the vacant d-orbital of the Cu(II) complex and the presence of lone-pair electrons on the ligand. 78 , 79 Similar trends were found in the TD-DFT-calculated absorption spectra ( Figures 1 and S9 ).…”
Section: Resultsmentioning
confidence: 99%
“…The cell suspension was incubated at room temperature in the dark for 15 min after mixing with 4 μL of Annexin V-FITC and 4 μL of PI. Subsequently, the samples were analyzed by a BD Accuri C6 flow cytometer …”
Section: Experimental and Computational Sectionmentioning
confidence: 99%
“…[9][10][11][12] Pt(II) and Pd(II) complexes composed of NNS tridentate pincer ligands were found to have significant biological activities. [13][14][15][16][17][18][19] Both metals have similar chemistry but the later has less side effects and better solubility, which led researchers to focus on Pd(II) complexes as antitumor drugs. [13][14][15][16][17][18][19] Palladium complexes [Pd II (HY)Cl] built from H 2 Y(SNN) pincer ligands were previously prepared in our laboratory.…”
Section: Introductionmentioning
confidence: 99%
“…[13][14][15][16][17][18][19] Both metals have similar chemistry but the later has less side effects and better solubility, which led researchers to focus on Pd(II) complexes as antitumor drugs. [13][14][15][16][17][18][19] Palladium complexes [Pd II (HY)Cl] built from H 2 Y(SNN) pincer ligands were previously prepared in our laboratory. 20 The ligand H 2 Y (Scheme 1, left) was bound in anionic form to Pd(II) to form neutral cis and trans isomers.…”
Section: Introductionmentioning
confidence: 99%